Longitudinal Analysis of the Associations between Antiretroviral Therapy,Viraemia and Immunosuppression with Lipid Levels: The D:A:D Study

Abstract

Background

Antiretroviral (ART) drugs have been associated with higher triglycerides (TG), higher total cholesterol (TC) and lower high-density lipoprotein cholesterol (HDL-C) levels. Associations between lipid levels with HIV viraemia and immunosuppression in the presence of ART remain unclear.

Methods

Participants from the D:A:D study with at least one TG/TC/HDL-C measurement were included. Linear mixed effect models were used to determine the association of ART, viral load (VL), nadir and current CD4⁺ T-cell count and previous AIDS diagnosis with lipids.

Results

Of 49,717 participants, 90%, 92% and 80% contributed at least one TG/TC/HDL-C measurement (median follow-up 6.8, 6.8 and 5.0 years, respectively). Predicted mean (95% CI) baseline levels for TG, TC and HDL-C (mmol/l), were 2.10 (2.05, 2.14), 4.94 (4.91, 4.98) and 1.08 (1.07, 1.10), respectively. Lopinavir was associated with the worst TG profile, (27.2% higher levels compared to atazanavir; 95% CI 25.2%, 29.2%), and darunavir had a similar profile as atazanavir. The nucleoside pair lamivudine/tenofovir was associated with the most favourable TG profile (-2.8%; -3.5%, -2.0%) compared with emtricitabine/tenofovir, whereas lamivudine/abacavir (+10.2%; +9.3%, +11.2%) and lamivudine/ stavudine (+8.0%; +6.9%, +9.0%), were associated with the worst. Raltegravir was associated with lower TG (-5.2%; -6.4%, -3.9%), and nevirapine had a more favourable HDL-C profile (+11.3%; +10.8%, +11.7%) than efavirenz (+5.3%; 5.0%, 5.7%), compared to atazanavir. Higher VLs were associated with lower TG/TC/HDL-C, whereas higher CD4⁺ T-cell counts were associated with higher TG/TC/HDL-C.

Conclusions

TG, TC and HDL-C levels, which generally improved over time, are dependent on ART, viraemia and, to a lesser extent, immunosuppression.

References

Fontas

, van Leth

, Sabin

C.A.

Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?

J Infect Dis 2004; 189: 1056–1074.

Nery

M.W.

, Martelli

C.M.

, Turchi

M.D.

Dyslipidemia in AIDS patients on highly active antiretroviral therapy.

Braz J Infect Dis 2011; 15: 151–155.

Riddler

S.A.

, Li

, Chu

Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.

HIV Med 2007; 8: 280–287.

Blanco

, San

R.J.

, Vispo

Management of metabolic complications and cardiovascular risk in HIV-infected patients.

AIDS Rev 2010; 12: 231–241.

Carr

Cardiovascular risk factors in HIV-infected patients.

J Acquir Immune Defic Syndr 2003; 34 Suppl 1: S73–S78.

Domingos

, Cunha

R.V.

, Paniago

A.M.

, Martins

D.M.

, Elkhoury

E.B.

, Souza

A.S.

Metabolic effects associated to the highly active antiretroviral therapy (HAART) in AIDS patients.

Braz J Infect Dis 2009; 13: 130–136.

Grunfeld

Dyslipidemia and its treatment in HIV infection.

Top HIV Med 2010; 18: 112–118.

Dyslipidemia and lipid management in HIV-infected patients.

Curr Opin Endocrinol Diabetes Obes 2011; 18: 144–147.

Williams

, Wu

, Cohn

Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution.

HIV Med 2009; 10: 290–301.

10.

El-Sadr

W.M.

, Mullin

C.M.

, Carr

Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort.

HIV Med 2005; 6: 114–121.

11.

Grunfeld

, Pang

, Doerrler

, Shigenaga

J.K.

, Jensen

, Feingold

K.R.

Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.

J Clin Endocrinol Metab 1992; 74: 1045–1052.

12.

Kuti

M.A.

, Adesina

O.A.

, Awolude

O.A.

Dyslipidemia in ART-naive HIV-infected persons in Nigeria – implications for care.

J Int Assoc Provid AIDS Care 2015; 14: 355–359.

13.

Crane

H.M.

, Grunfeld

, Willig

J.H.

Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care.

AIDS 2011; 25: 185–195.

14.

Floris-Moore

, Howard

A.A.

, Lo

, Arnsten

J.H.

, Santoro

, Schoenbaum

E.E.

Increased serum lipids are associated with higher CD4 lymphocyte count in HIV-infected women.

HIV Med 2006; 7: 421–430.

15.

Friis-Møller

, Weber

, Reiss

Cardiovascular disease risk factors in HIV patients–association with antiretroviral therapy. Results from the DAD study.

AIDS 2003; 17: 1179–1193.

16.

Friis-Møller

, Sabin

C.A.

, Weber

Combination antiretroviral therapy and the risk of myocardial infarction.

N Engl J Med 2003; 349: 1993–2003.

17.

Thiébaut

, Walker

When it is better to estimate a slope with only one point.

QJM 2008; 101: 821–824.

18.

Armitage

, Berry

, Matthews

J.N.

Statistical methods in medical research. 4th addition. London: Blackwell Science 2008.

19.

Greub

, Cozzi-Lepri

, Ledergerber

Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy.

AIDS 2002; 16: 1967–1969.

20.

Laird

N.M.

, Ware

J.H.

Random-effects models for longitudinal data.

Biometrics 1982; 38: 963–974.

21.

Riddler

S.A.

, Li

, Chu

Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.

HIV Med 2007; 8: 280–287.

22.

Cohen

J.D.

, Cziraky

M.J.

, Cai

30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006.

Am J Cardiol 2010; 106: 969–975.

23.

Feinstein

M.J.

, Achenbach

C.J.

, Stone

N.J.

, Lloyd-Jones

D.M.

A systematic review of the usefulness of statin therapy in HIV-infected patients.

Am J Cardiol 2015; 115: 1760–1766.

24.

Mulligan

, Grunfeld

, Tai

V.W.

Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.

J Acquir Immune Defic Syndr 2000; 23: 35–43.

25.

Savès

, Chene

, Ducimetiere

Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population.

Clin Infect Dis 2003; 37: 292–298.

26.

Vilela

F.D.

, Lorenzo

A.R.

, Tura

B.R.

Risk of coronary artery disease in individuals infected with human immunodeficiency virus.

Braz J Infect Dis 2011; 15: 521–527.

27.

Grinspoon

, Carr

Cardiovascular risk and body-fat abnormalities in HIV-infected adults.

N Engl J Med 2005; 352: 48–62.

28.

Dragsted

U.B.

, Gerstoft

, Pedersen

Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.

J Infect Dis 2003; 188: 635–642.

29.

Magenta

, Dell-Kuster

, Richter

W.O.

Lipid and lipoprotein profile in HIV-infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy.

AIDS Res Hum Retroviruses 2011; 27: 525–533.

30.

Overton

E.T.

, Arathoon

, Baraldi

, Tomaka

Effect of darunavir on lipid profile in HIV-infected patients.

HIV Clin Trials 2012; 13: 256–270.

31.

Purnell

J.Q.

, Zambon

, Knopp

R.H.

Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.

AIDS 2000; 14: 51–57.

32.

Lee

G.A.

, Seneviratne

, Noor

M.A.

The metabolic effects of lopinavir/ritonavir in HIV-negative men.

AIDS 2004; 18: 641–649.

33.

Mallolas

, Podzamczer

, Milinkovic

Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.

J Acquir Immune Defic Syndr 2009; 51: 29–36.

34.

de Saint-Martin

, Bressollette

, Perfezou

Impact of atazanavir-based HAART regimen on the carotid intima-media thickness of HIV-infected persons: a comparative prospective cohort.

AIDS 2010; 24: 2797–2801.

35.

Estrada

, Portilla

Dyslipidemia related to antiretroviral therapy.

AIDS Rev 2011; 13: 49–56.

36.

Crane

H.M.

, Grunfeld

, Willig

J.H.

Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care.

AIDS 2011; 25: 185–195.

37.

Maggi

, Bellacosa

, Carito

Cardiovascular risk factors in patients on long-term treatment with nevirapine-or efavirenz-based regimens.

J Antimicrob Chemother 2011; 66: 896–900.

38.

van Leth

, Phanuphak

, Stroes

Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.

PLoS Med 2004; 1: e19.

39.

Manfredi

, Calza

, Marinacci

Raltegravir use prospectively assessed in a major HIV outpatient clinic in Italy: sample population, virological-immunological activity, and tolerability profile.

Infez Med 2014; 22: 288–295.

40.

Rockstroh

J.K.

, Lennox

J.L.

, DeJesus

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

Clin Infect Dis 2011; 53: 807–816.

41.

Lampe

F.C.

, Duprez

D.A.

, Kuller

L.H.

Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy.

J Acquir Immune Defic Syndr 2010; 54: 275–284.

42.

Lundgren

J.D.

, Babiker

, El-Sadr

Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.

J Infect Dis 2008; 197: 1145–1155.

43.

Silverberg

M.J.

, Leyden

W.A.

, Xu

Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care.

J Acquir Immune Defic Syndr 2014; 65: 160–166.

44.

Gordon

D.J.

, Probstfield

J.L.

, Garrison

R.J.

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.

Circulation 1989; 79: 8–15.

45.

Manninen

, Elo

M.O.

, Frick

M.H.

Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.

JAMA 1988; 260: 641–651.

46.

Friis-Møller

, Thiebaut

, Reiss

Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.

Eur J Cardiovasc Prev Rehabil 2010; 17: 491–501.

47.

Worm

S.W.

, Kamara

D.A.

, Reiss

Elevated triglycerides and risk of myocardial infarction in HIV-positive persons.

AIDS 2011; 25: 1497–1504.

48.

Friedewald

W.T.

, Levy

R.I.

, Fredrickson

D.S.

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Clin Chem 1972; 18: 499–502.

49.

Garg

, Joshi

, Mukherjee

Cardiovascular complications of HIV infection and treatment.

Cardiovasc Hematol Agents Med Chem 2013; 11: 58–66.

50.

Paiardini

, Muller-Trutwin

HIV-associated chronic immune activation.

Immunol Rev 2013; 254: 78–101.